PMID- 30903198
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Linking)
VI  - 46
IP  - 6
DP  - 2019 Jun
TI  - Low hexokinase-2 expression-associated false-negative (18)F-FDG PET/CT as a 
      potential prognostic predictor in patients with multiple myeloma.
PG  - 1345-1350
LID - 10.1007/s00259-019-04312-9 [doi]
AB  - PURPOSE: False-negative (18)F-FDG PET/CT, which is associated with low 
      hexokinase-2 (HK2) expression in multiple myeloma (MM), is a new concept that is 
      relevant for diagnosis and treatment response assessment. This study aimed to 
      investigate the prognostic relevance of low HK2 expression-associated 
      false-negative PET/CT in patients with MM. METHODS: Ninety consecutive patients, 
      with newly diagnosed MM, receiving novel agents during induction therapy were 
      enrolled in this retrospective study. Patients were divided into three groups 
      according to the combination of the positivity of PET/CT and whole-body 
      diffusion-weighted magnetic resonance imaging (DWMRI), namely, negative DWMRI, 
      false-negative PET/CT, and positive PET/CT. RESULTS: False-negative PET/CT was 
      observed in 12% patients who were older, had documented clinical history of 
      smouldering MM, and showed lower HK2 expression levels than the positive PET/CT 
      patients. False-negative PET/CT patients showed a clear trend of longer time to 
      next treatment (TTNT) and progression-free survival (PFS) than the positive 
      PET/CT patients (P = 0.035 and 0.071, respectively). Furthermore, TTNT and PFS of 
      false-negative PET/CT patients were similar to those of patients without 
      established high-risk PET/CT findings and significantly longer than those of 
      high-risk PET/CT patients (P = 0.013 and 0.047, respectively). CONCLUSIONS: This 
      study showed, for the first time, that low HK2 expression-associated 
      false-negative PET/CT was associated with relatively better prognosis in patients 
      with newly diagnosed MM, suggesting that this phenomenon may not undermine the 
      established PET/CT-based prognostication. Furthermore, this phenomenon may be 
      useful for identifying patients at lower risk of disease progression among those 
      with myelomatous lesions on DWMRI.
FAU - Abe, Yoshiaki
AU  - Abe Y
AUID- ORCID: 0000-0002-1021-7911
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan. 
      yoshiakiabe1018@gmail.com.
FAU - Ikeda, Sho
AU  - Ikeda S
AD  - Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate 
      School of Medicine, Akita, Japan.
FAU - Kitadate, Akihiro
AU  - Kitadate A
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.
FAU - Narita, Kentaro
AU  - Narita K
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.
FAU - Kobayashi, Hiroki
AU  - Kobayashi H
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.
FAU - Miura, Daisuke
AU  - Miura D
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.
FAU - Takeuchi, Masami
AU  - Takeuchi M
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.
FAU - O'uchi, Eri
AU  - O'uchi E
AD  - Department of Radiology, Kameda Medical Center, Kamogawa, Japan.
FAU - O'uchi, Toshihiro
AU  - O'uchi T
AD  - Department of Radiology, Kameda Medical Center, Kamogawa, Japan.
FAU - Matsue, Kosei
AU  - Matsue K
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190322
PL  - Germany
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.1.1 (Hexokinase)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Diffusion Magnetic Resonance Imaging
MH  - False Negative Reactions
MH  - Female
MH  - Fluorodeoxyglucose F18/*analysis
MH  - Hexokinase/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*diagnostic imaging/enzymology
MH  - *Positron Emission Tomography Computed Tomography
MH  - Prognosis
MH  - Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - False-negative
OT  - Hexokinase-2
OT  - Multiple myeloma
OT  - Positron emission tomography/computed tomography
OT  - Prognosis
EDAT- 2019/03/25 06:00
MHDA- 2020/07/21 06:00
CRDT- 2019/03/24 06:00
PHST- 2019/01/28 00:00 [received]
PHST- 2019/03/08 00:00 [accepted]
PHST- 2019/03/25 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2019/03/24 06:00 [entrez]
AID - 10.1007/s00259-019-04312-9 [pii]
AID - 10.1007/s00259-019-04312-9 [doi]
PST - ppublish
SO  - Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1345-1350. doi: 
      10.1007/s00259-019-04312-9. Epub 2019 Mar 22.